- Home
- AKBA vs MBI Comparison
AKBA vs MBI Comparison
Compare AKBA & MBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- MBI
- Stock Information
- Founded
- AKBA 2007
- MBI 1973
- Country
- AKBA United States
- MBI United States
- Employees
- AKBA N/A
- MBI N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- MBI Property-Casualty Insurers
- Sector
- AKBA Health Care
- MBI Finance
- Exchange
- AKBA Nasdaq
- MBI Nasdaq
- Market Cap
- AKBA 336.2M
- MBI N/A
- IPO Year
- AKBA 2014
- MBI 1987
- Fundamental
- Price
- AKBA $1.93
- MBI $4.83
- Analyst Decision
- AKBA Strong Buy
- MBI Buy
- Analyst Count
- AKBA 3
- MBI 2
- Target Price
- AKBA $6.50
- MBI $6.75
- AVG Volume (30 Days)
- AKBA 6.1M
- MBI 280.9K
- Earning Date
- AKBA 05-08-2025
- MBI 05-08-2025
- Dividend Yield
- AKBA N/A
- MBI N/A
- EPS Growth
- AKBA N/A
- MBI N/A
- EPS
- AKBA N/A
- MBI N/A
- Revenue
- AKBA $160,180,000.00
- MBI $27,000,000.00
- Revenue This Year
- AKBA $23.40
- MBI N/A
- Revenue Next Year
- AKBA $58.44
- MBI N/A
- P/E Ratio
- AKBA N/A
- MBI N/A
- Revenue Growth
- AKBA N/A
- MBI 285.71
- 52 Week Low
- AKBA $0.80
- MBI $3.22
- 52 Week High
- AKBA $2.89
- MBI $7.46
- Technical
- Relative Strength Index (RSI)
- AKBA 46.74
- MBI 32.96
- Support Level
- AKBA $1.83
- MBI $4.66
- Resistance Level
- AKBA $1.99
- MBI $5.58
- Average True Range (ATR)
- AKBA 0.19
- MBI 0.26
- MACD
- AKBA -0.03
- MBI -0.02
- Stochastic Oscillator
- AKBA 15.42
- MBI 16.50
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.